

CMS FINALIZES HIGHER PAYMENT FOR CERAMENT® G IN THE US

BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces that the U.S. Centers for Medicare & Medicaid Services (CMS) has confirmed the proposed DRG reassignment for CERAMENT® G in the pre-published final Medicare Inpatient Prospective Payment System (IPPS) rule for fiscal year 2027. The decision means that qualifying CERAMENT G cases will be assigned to the highest reimbursing Diagnosis-Related Groups (DRGs) within their respective clinical categories.

The DRG reassignment will apply to gentamicin-eluting bone void fillers, a category in which CERAMENT G is currently the only product. The change is expected to improve hospital reimbursement for the use of CERAMENT G in the treatment of complex orthopedic infections - including periprosthetic joint infection (PJI), fracture-related infection (FRI), and diabetes-related bone infection.

The final rule also confirms the establishment of a new procedure code for vancomycin-eluting bone void fillers. If the FDA grants De Novo classification for CERAMENT® V, the product is expected to be the first and only therapy eligible under this code and to qualify for the same DRG reassignment as CERAMENT G. As a result, BONESUPPORT expects that a future New Technology Add-on Payment (NTAP) application for CERAMENT V will no longer be necessary.

The final rule takes effect on October 1, 2026.

For more information contact:

BONESUPPORT AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
03 August 2026 08:00:00 CEST



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

CMS FINALIZES HIGHER PAYMENT FOR CERAMENT® G IN THE US